Olinger Margaret 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Jan 10, 2023
Insider Transaction Report
Form 4
Olinger Margaret
Chief Commercial Officer
Transactions
- Sale
Common Stock
2023-01-06$36.08/sh+1,660$59,891→ 215,098 total - Sale
Common Stock
2023-01-06$36.79/sh+743$27,334→ 214,355 total
Footnotes (3)
- [F1]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.